All In Biotech

Drug Trial Radar · NCT01130272

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea

Last checked: Nov 20, 2026Latest source record: Oct 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 807 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

807

Actual

Start

Apr 28, 2010

Primary completion

Jul 14, 2011

Study completion Jul 14, 2011

Sponsor

Lead sponsor
Furiex Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
May 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).

Conditions

  • Irritable Bowel Syndrome

Interventions

  • EluxadolineDrug

    Tablets, orally, twice daily.

  • PlaceboDrug

    Matching placebo oral tablets twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4Time frame: Baseline (Week prior to Randomization) to Week 4
  2. Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 12Time frame: Baseline (Week prior to Randomization) to Week 12

Locations

288 sites in 1 country. Site status is shown where the registry gives one.

  • Furiex Research Site

    Anniston, Alabama

  • Furiex Research Site

    Birmingham, Alabama

  • Furiex Research Site

    Birmingham, Alabama

  • Furiex Research Site

    Dothan, Alabama

  • Furiex Research Site

    Huntsville, Alabama

  • Furiex Research Site

    Huntsville, Alabama

  • Furiex Research Site

    Mobile, Alabama

  • Furiex Research Site

    Montgomery, Alabama

  • Furiex Research Site

    Pell City, Alabama

  • Furiex Research Site

    Chandler, Arizona

  • Furiex Research Site

    Glendale, Arizona

  • Furiex Research Site

    Mesa, Arizona

  • Furiex Research Site

    Phoenix, Arizona

  • Furiex Research Site

    Phoenix, Arizona

  • Furiex Research Site

    Phoenix, Arizona

  • Furiex Research Site

    Tempe, Arizona

  • Furiex Research Site

    Tempe, Arizona

  • Furiex Research Site

    Tucson, Arizona

  • Furiex Research Site

    Tucson, Arizona

  • Furiex Research Site

    Jonesboro, Arkansas

  • Furiex Research Site

    Little Rock, Arkansas

  • Furiex Research Site

    Searcy, Arkansas

  • Furiex Research Site

    Sherwood, Arkansas

  • Furiex Research Site

    Aliso Viejo, California

  • Furiex Research Site

    Anaheim, California

  • Furiex Research Site

    Azusa, California

  • Furiex Research Site

    Burbank, California

  • Furiex Research Site

    Carlsbad, California

  • Furiex Research Site

    Encinitas, California

  • Furiex Research Site

    Garden Grove, California

  • Furiex Research Site

    Garden Grove, California

  • Furiex Research Site

    Inglewood, California

  • Furiex Research Site

    Laguna Hills, California

  • Furiex Research Site

    Long Beach, California

  • Furiex Research Site

    Los Angeles, California

  • Furiex Research Site

    Los Angeles, California

  • Furiex Research Site

    Murrieta, California

  • Furiex Research Site

    Oakland, California

  • Furiex Research Site

    Orange, California

  • Furiex Research Site

    Sacramento, California

Showing 40 of 288 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.